

REMARKS

Claim 105 is pending. Non-elected claims 106-109 are canceled without prejudice.

Claim 105 is amended. New claims 110 and 111 are added, supported at least at p. 7 ¶19, p.13 ¶41, p. 14 ¶44, p. 16 ¶47, thus introducing no new matter.

CLAIM REJECTIONS UNDER 35 U.S.C. §112

Claim 105 is rejected under 35 U.S.C. §112 ¶1 as not enabled.

Applicants have amended claim 105 and have included a Declaration under 37 C.F.R. §1.132.

The Declaration states that one skilled in the art would know, or could determine without undue experimentation, how to determine a sequence for each of a human gene encoding a superoxide dismutase and a human gene encoding a catalase. The Declaration states that one skilled in the art could determine, without undue experimentation, if a polymorphism in a human gene encoding a superoxide dismutase and a human gene encoding a catalase was identified as associated with any pathology.

Claim 1 (Applicants believe this refers to claim 105, not claim 1, which is canceled) is rejected under 35 U.S.C. §112 ¶2 as indefinite in reciting "increased dose".

Applicants have deleted "increase dose" to overcome the rejection.

Applicants believe they have addressed each basis of the Examiner's rejection, and respectfully request its withdrawal.

CONCLUSION

Applicants authorize credit card fee payment for fees due with this submission (see Electronic Fee Calculation Sheet). If other fees are due, the Examiner is authorized to charge them (or credit any overpayment) to Deposit Account No. 23-3000.

The Examiner is invited to contact Applicants' undersigned representative with questions.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

/Beverly A. Lyman/

Beverly A. Lyman, Ph.D.
Reg. No. 41,961

2700 Carew Tower
441 Vine Street
Cincinnati OH 45202
513 241 2324
513 241 6234 facsimile